Immunotherapy and immunochemotherapy in visceral leishmaniasis: Promising treatments for this neglected disease

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Roatt, Bruno Mendes ^a,b   Aguiar Soares, Rodrigo Dian de Oliveira ^a   Coura Vital, Wendel ^a   Ker, Henrique Gama ^a   Moreira, Nádia das Dores ^a   Vitoriano Souza, Juliana ^a   Giunchetti, Rodolfo Cordeiro ^a,c   Carneiro, Cláudia Martins ^a   Reis, Alexandre Barbosa ^a,b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b Instituto de Pesquisas René Rachou   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Immunochemotherapy; Immunology; Immunotherapy; Leishmania donovani; Leishmania infantum; Visceral leishmaniasis

Indexed keywords

EID: 84905664328     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00272     Document Type: Review

References (138)

1. van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am (2012) 26(2):309-22. doi: 10.1016/j.idc.2012.03.005
2. Dujardin JC, Campino L, Canavate C, Dedet JP, Gradoni L, Soteriadou K, et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis (2008) 14(7):1013-8. doi:10.3201/eid1407.071589
3. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis (2004) 27(5):305-18. doi:10.1016/j.cimid.2004.03.004
4. Laurenti MD, Rossi CN, Matta VL, Tomokane TY, Corbett CE, Secundino NF, et al. Asymptomatic dogs are highly competent to transmit Leishmania (Leishmania) infantum chagasi to the natural vector. Vet Parasitol (2013) 196(3-4):296-300. doi:10.1016/j.vetpar.2013.03.017
5. Molina R, Amela C, Nieto J, San-Andres M, Gonzalez F, Castillo JA, et al. Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus. Trans R Soc Trop Med Hyg (1994) 88(4):491-3. doi:10.1016/0035-9203(94)90446-4
6. Solano-Gallego L, Koutinas A, Miro G, Cardoso L, Pennisi MG, Ferrer L, et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol (2009) 165(1-2):1-18. doi:10.1016/j.vetpar.2009.05.022
7. Dantas-Torres F, Solano-Gallego L, Baneth G, Ribeiro VM, de Paiva-Cavalcanti M, Otranto D. Canine leishmaniosis in the Old and New Worlds: unveiled similarities and differences. Trends Parasitol (2012) 28(12):531-8. doi:10.1016/j.pt.2012.08.007
8. Freeman KS, Miller MD, Breitschwerdt EB, Lappin MR. Leishmaniasis in a dog native to Colorado. J Am Vet Med Assoc (2010) 237(11):1288-91. doi:10.2460/javma.237.11.1288
9. Duprey ZH, Steurer FJ, Rooney JA, Kirchhoff LV, Jackson JE, Rowton ED, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis (2006) 12(3):440-6. doi:10.3201/eid1203.050811
10. Baldelli R, Piva S, Salvatore D, Parigi M, Melloni O, Tamba M, et al. Canine leishmaniasis surveillance in a northern Italy kennel. Vet Parasitol (2011) 179(1-3):57-61. doi:10.1016/j.vetpar.2011.01.052
11. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health (2008) 13(2):256-64. doi:10.1111/j.1365-3156.2007.01998.x
12. Malaquias LC, do Carmo Romualdo R, do Anjos JB Jr, Giunchetti RC, Correa-Oliveira R, Reis AB. Serological screening confirms the re-emergence of canine leishmaniosis in urban and rural areas in Governador Valadares, Vale do Rio Doce, Minas Gerais, Brazil. Parasitol Res (2007) 100(2):233-9. doi:10.1007/s00436-006-0259-z
13. Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol (2001) 39(2):560-3. doi:10.1128/JCM.39.2.560-563.2001
14. Coura-Vital W, Marques MJ, Veloso VM, Roatt BM, Aguiar-Soares RD, Reis LE, et al. Prevalence and factors associated with Leishmania infantum infection of dogs from an urban area of Brazil as identified by molecular methods. PLoS Negl Trop Dis (2011) 5(8):e1291. doi:10.1371/journal.pntd.0001291
15. Coura-Vital W, Reis AB, Fausto MA, Leal GG, Marques MJ, Veloso VM, et al. Risk factors for seroconversion by Leishmania infantum in a Cohort of dogs from an endemic area of Brazil. PLoS One (2013) 8(8):e71833. doi:10.1371/journal.pone.0071833
16. Coura-Vital W, Reis AB, Reis LE, Braga SL, Roatt BM, Aguiar-Soares RD, et al. Canine visceral leishmaniasis: incidence and risk factors for infection in a cohort study in Brazil. Vet Parasitol (2013) 197(3-4):411-7. doi:10.1016/j.vetpar.2013.07.031
17. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 7(5):e35671. doi:10.1371/journal.pone.0035671
18. Gramiccia M, Scalone A, Di Muccio T, Orsini S, Fiorentino E, Gradoni L. The burden of visceral leishmaniasis in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Euro Surveill (2013) 18(29):20535.
19. Bogdan C, Schonian G, Banuls AL, Hide M, Pratlong F, Lorenz E, et al. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis (2001) 32(2):302-6. doi:10.1086/318476
20. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 21(2):334-59. doi:10.1128/CMR.00061-07
21. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) (2001) 80(1):54-73. doi:10.1097/00005792-200101000-00006
22. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet (2005) 366(9496):1561-77. doi:10.1016/S0140-6736(05)67629-5
23. Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, et al. Serum cytokines associated with severity and complications of kala-azar. Pathog Glob Health (2013) 107(2):78-87. doi:10.1179/2047773213Y.0000000078
24. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg (2003) 69(6):624-8.
25. Barnett PG, Singh SP, Bern C, Hightower AW, Sundar S. Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 73(4):720-5.
26. Ministério da saúde. Sistema de Informação de Agravos de Notificação - Sinan Net. (2013) [cited 2013 December 2]. Available from: http://dtr2004.saude.gov.br/sinanweb/tabnet/tabnet?sinannet/leishvi/bases/leishvbrnet.def
27. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, et al. The immunopathology of experimental visceral leishmaniasis. Immunol Rev (2004) 201:239-53. doi:10.1111/j.0105-2896.2004.00188.x
28. Stager S, Joshi T, Bankoti R. Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunol Res (2010) 47(1-3):14-24. doi:10.1007/s12026-009-8135-4
29. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis (2010) 2(2):135-46. doi:10.4103/0974-777X.62876
30. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD Jr. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest (1989) 83(3):860-4. doi:10.1172/JCI113969
31. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis (1996) 173(6):1515-8. doi:10.1093/infdis/173.6.1515
32. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol (2007) 28(9):378-84. doi:10.1016/j.it.2007.07.004
33. Pinelli E, Killick-Kendrick R, Wagenaar J, Bernadina W, del Real G, Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun (1994) 62(1): 229-35.
34. Pinelli E, van der Kaaij SY, Broeren CP, Ruitenberg EJ, Rutten VP. Measurement of dog cytokines by reverse transcription-quantitative competitive polymerase chain reaction. Immunogenetics (1999) 49(7-8):696-9. doi:10.1007/s002510050667
35. Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Carvalho MG, Mayrink W, Franca-Silva JC, et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci (2006) 81(1):68-75. doi:10.1016/j.rvsc.2005.09.011
36. Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Giunchetti RC, Carneiro CM, Mayrink W, et al. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol (2009) 128(1-3):87-95. doi:10.1016/j.vetimm.2008.10.307
37. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Rev Soc Bras Med Trop (2013) 46(2):128-34. doi:10.1590/0037-8682-0022-2012
38. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol (2005) 62(5):487-95. doi:10.1111/j.1365-3083.2005.01686.x
39. Manna PP, Chakrabarti G, Bandyopadhyay S. Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell. Vaccine (2010) 28(3):803-10. doi:10.1016/j.vaccine.2009.10.053
40. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis (1997) 175(6):1477-9. doi:10.1086/516482
41. Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev (2000) 173:17-26. doi:10.1034/j.1600-065X.2000.917307.x
42. Brandonisio O, Panaro MA, Fumarola I, Sisto M, Leogrande D, Acquafredda A, et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med (2002) 2(3):125-9. doi:10.1007/s102380200017
43. Medeiros IM, Reed S, Castelo A, Salomao R. Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis. Clin Microbiol Infect (2000) 6(1):34-7. doi:10.1046/j.1469-0691.2000.00011.x
44. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 119(8):2379-87. doi:10.1172/JCI38813
45. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 186(7):3977-85. doi:10.4049/jimmunol.1003588
46. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2014) 209(2):290-9. doi:10.1093/infdis/jit401
47. Racoosin EL, Beverley SM. Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp Parasitol (1997) 85(3):283-95. doi:10.1006/expr.1996.4139
48. Antoniazi S, Price HP, Kropf P, Freudenberg MA, Galanos C, Smith DF, et al. Chemokine gene expression in toll-like receptor-competent and -deficient mice infected with Leishmania major. Infect Immun (2004) 72(9):5168-74. doi:10.1128/IAI.72.9.5168-5174.2004
49. Menezes-Souza D, Guerra-Sa R, Carneiro CM, Vitoriano-Souza J, Giunchetti RC, Teixeira-Carvalho A, et al. Higher expression of CCL2, CCL4, CCL5, CCL21, and CXCL8 chemokines in the skin associated with parasite density in canine visceral leishmaniasis. PLoS Negl Trop Dis (2012) 6(4):e1566. doi:10.1371/journal.pntd.0001566
50. Stanley AC, Engwerda CR. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol (2007) 85(2):138-47. doi:10.1038/sj.icb7100011
51. Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg (2004) 71(5):561-7.
52. Strauss-Ayali D, Baneth G, Jaffe CL. Splenic immune responses during canine visceral leishmaniasis. Vet Res (2007) 38(4):547-64. doi:10.1051/vetres:2007015
53. Ritter U, Moll H. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur J Immunol (2000) 30(11):3111-20. doi:10.1002/1521-4141(200011)30:11<3111::AID-IMMU3111>3.0.CO;2-O
54. Trinchieri G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol (1997) 9(1):17-23. doi:10.1016/S0952-7915(97)80154-9
55. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG. Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol (1993) 71(Pt 6):583-7. doi:10.1038/icb.1993.64
56. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 174(5):1209-20. doi:10.1084/jem.174.5.1209
57. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174(4):915-24. doi:10.1084/jem.174.4.915
58. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol (1995) 154(10):5320-30.
59. World Health Organization. Control of the Leishmaniasis: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: WHO (2010). p. 202. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf
60. Singh N, Kumar M, Singh RK. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med (2012) 5(6):485-97. doi:10.1016/S1995-7645(12)60084-4
61. Fraga DB, Solca MS, Silva VM, Borja LS, Nascimento EG, Oliveira GG, et al. Temporal distribution of positive results of tests for detecting Leishmania infection in stray dogs of an endemic area of visceral leishmaniasis in the Brazilian tropics: a 13 years survey and association with human disease. Vet Parasitol (2012) 190(3-4):591-4. doi:10.1016/j.vetpar.2012.06.025
62. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis (1996) 22(6):938-43. doi:10.1093/clinids/22.6.938
63. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med (1999) 341(24):1795-800. doi:10.1056/NEJM199912093412403
64. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 347(22):1739-46. doi:10.1056/NEJMoa021556
65. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 316(7139):1200-5. doi:10.1136/bmj.316.7139.1200
66. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol (2006) 61:223-74. doi:10.1016/S0065-308X(05)61006-8
67. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 19(1):111-26. doi:10.1128/CMR.19.1.111-126.2006
68. Matoussi N, Ameur HB, Amor SB, Fitouri Z, Becher SB. Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report. Med Mal Infect (2007) 37(Suppl 3):S257-9. doi:10.1016/j.medmal.2007.08.001
69. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis (1994) 18(1):83-90. doi:10.1093/clinids/18.1.83
70. Zaghloul IY, Al-Jasser M. Effect of renal impairment on the pharmacokinetics of antimony in hamsters. Ann Trop Med Parasitol (2004) 98(8):793-800. doi:10.1179/000349804X3171
71. Mancianti F, Gramiccia M, Gradoni L, Pieri S. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans R Soc Trop Med Hyg (1988) 82(4):566-7. doi:10.1016/0035-9203(88)90510-X
72. Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimoniate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Vet Q (1997) 19(1):10-3. doi:10.1080/01652176.1997.9694729
73. Carrio J, Portus M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol (2002) 2:11. doi:10.1186/1471-2210-2-11
74. da Silva SM, Amorim IF, Ribeiro RR, Azevedo EG, Demicheli C, Melo MN, et al. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis. Antimicrob Agents Chemother (2012) 56(6):2858-67. doi:10.1128/AAC.00208-12
75. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis (2009) 48(2):e16-22. doi:10.1086/595710
76. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis (2007) 45(5):556-61. doi:10.1086/520665
77. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, et al. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg (2010) 83(2):357-64. doi:10.4269/ajtmh.2010.10-0156
78. Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother (1995) 36(6):1013-9. doi:10.1093/jac/36.6.1013
79. Rigo RS, Carvalho CM, Honer MR, Andrade GB, Silva IS, Rigo L, et al. Renal histopathological findings in dogs with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo (2013) 55(2):113-6. doi:10.1590/S0036-46652013000200008
80. Cortadellas O. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. J Vet Intern Med (2003) 17(6):808-12. doi:10.1111/j.1939-1676.2003.tb02518.x
81. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol (2003) 19(11):502-8. doi:10.1016/j.pt.2003.09.008
82. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg (2006) 100(Suppl 1):S26-33. doi:10.1016/j.trstmh.2006.02.011
83. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother (2004) 48(8):3010-5. doi:10.1128/AAC.48.8.3010-3015.2004
84. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag (2007) 3(5):733-40.
85. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem (2003) 278(50):49965-71. doi:10.1074/jbc.M308352200
86. Andrade HM, Toledo VP, Pinheiro MB, Guimaraes TM, Oliveira NC, Castro JA, et al. Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil. Vet Parasitol (2011) 181(2-4):83-90. doi:10.1016/j.vetpar.2011.05.009
87. Farca AM, Miniscalco B, Badino P, Odore R, Monticelli P, Trisciuoglio A, et al. Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. Parasitol Res (2012) 110(6):2509-13. doi:10.1007/s00436-011-2792-7
88. Woerly V, Maynard L, Sanquer A, Eun HM. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res (2009) 105(2):463-9. doi:10.1007/s00436-009-1404-2
89. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 4(10):e709. doi:10.1371/journal.pntd.0000709
90. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs (2008) 17(5):787-94. doi:10.1517/13543784.17.5.787
91. Fernandez MM, Malchiodi EL, Algranati ID. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother (2011) 55(1):86-93. doi:10.1128/AAC.00506-10
92. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med (2007) 356(25):2571-81. doi:10.1056/NEJMoa066536
93. Poli A, Sozzi S, Guidi G, Bandinelli P, Mancianti F. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Vet Parasitol (1997) 71(4):263-71. doi:10.1016/S0304-4017(97)00014-9
94. Vexenat JA, Olliaro PL, Fonseca de Castro JA, Cavalcante R, Furtado Campos JH, Tavares JP, et al. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). Am J Trop Med Hyg (1998) 58(4):448-53.
95. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg (2007) 101(1):19-24. doi:10.1016/j.trstmh.2006.02.005
96. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist (2012) 2:11-9. doi:10.1016/j.ijpddr.2012.01.003
97. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother (2013) 14(1):53-63. doi:10.1517/14656566.2013.755515
98. Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L, et al. Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc (2010) 236(11):1192-8. doi:10.2460/javma.236.11.1192
99. Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy (2009) 1(5):765-76. doi:10.2217/imt.09.40
100. Oldham RK. Biologicals: new horizons in pharmaceutical development. J Biol Response Mod (1983) 2(3):199-206.
101. Oldham RK, Smalley RV. Immunotherapy: the old and the new. J Biol Response Mod (1983) 2(1):1-37.
102. El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr Med Assoc J (2009) 11(10):623-8.
103. Genaro O, de Toledo VP, da Costa CA, Hermeto MV, Afonso LC, Mayrink W. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol (1996) 14(5):503-12. doi:10.1016/0738-081X(96)00040-5
104. Convit J, Castellanos PL, Rondon A, Pinardi ME, Ulrich M, Castes M, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet (1987) 1(8530):401-5. doi:10.1016/S0140-6736(87)90116-4
105. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg (2003) 97(4):469-72. doi:10.1016/S0035-9203(03)90093-9
106. Mayrink W, Magalhaes PA, Michalick MS, da Costa CA, Lima Ade O, Melo MN, et al. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parassitologia (1992) 34(1-3):159-65.
107. Mayrink W, Botelho AC, Magalhaes PA, Batista SM, Lima Ade O, Genaro O, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop (2006) 39(1):14-21. doi:10.1590/S0037-86822006000100003
108. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg (2008) 102(1):58-63. doi:10.1016/j.trstmh.2007.08.006
109. Dalton JE, Kaye PM. Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev Anti Infect Ther (2010) 8(7):739-42. doi:10.1586/eri.10.64
110. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 72(4):1506-10. doi:10.1172/JCI111107
111. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med (1994) 97(5):459-67. doi:10.1016/0002-9343(94)90326-3
112. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis (1994) 170(3):659-62. doi:10.1093/infdis/170.3.659
113. Badaro R. The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis. Mem Inst Oswaldo Cruz (1988) 83(Suppl 1):376-7. doi:10.1590/S0074-02761988000500028
114. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis (1997) 176(4):1117-9. doi:10.1086/516526
115. Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. Vet Parasitol (2002) 106(4):315-24. doi:10.1016/S0304-4017(02)00115-2
116. Riera C, Valladares JE, Gallego M, Aisa MJ, Castillejo S, Fisa R, et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol (1999) 84(1-2):33-47. doi:10.1016/S0304-4017(99)00084-9
117. Guarga JL, Moreno J, Lucientes J, Gracia MJ, Peribanez MA, Castillo JA. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol (2002) 88(1-2):13-20. doi:10.1016/S0165-2427(02)00128-9
118. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E, Hashimoto Okada LY, de A Trivellato FA, Kawasaki JK, et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine (2004) 22(17-18):2234-43. doi:10.1016/j.vaccine.2003.11.039
119. Santos FN, Borja-Cabrera GP, Miyashiro LM, Grechi J, Reis AB, Moreira MA, et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine (2007) 25(33):6176-90. doi:10.1016/j.vaccine.2007.06.005
120. Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, et al. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine (2010) 28(3):597-603. doi:10.1016/j.vaccine.2009.09.071
121. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med (1990) 322(1):16-21. doi:10.1056/NEJM199001043220104
122. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg (1993) 48(5):666-9.
123. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis (1995) 172(6):1627-9. doi:10.1093/infdis/172.6.1627
124. Miret J, Nascimento E, Sampaio W, Franca JC, Fujiwara RT, Vale A, et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine (2008) 26(12):1585-94. doi:10.1016/j.vaccine.2008.01.026
125. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine (2010) 28(19):3333-40. doi:10.1016/j.vaccine.2010.02.089
126. Santiago ME, Neto LS, Alexandre EC, Munari DP, Andrade MM, Somenzari MA, et al. Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA. Acta Trop (2013) 127(3):174-80. doi:10.1016/j.actatropica.2013.04.005
127. Favaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Duran N, et al. Effects of P-MAPA immunomodulator on toll-like receptors and p53: potential therapeutic strategies for infectious diseases and cancer. Infect Agent Cancer (2012) 7(1):14. doi:10.1186/1750-9378-7-14
128. Roatt BM, Aguiar-Soares RD, Vitoriano-Souza J, Coura-Vital W, Braga SL, Correa-Oliveira R, et al. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation. PLoS One (2012) 7(11):e49780. doi:10.1371/journal.pone.0049780
129. Aguiar-Soares RD, Roatt BM, Ker HG, Moreira N, Mathias FA, Cardoso JM, et al. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4(+) and CD8(+)) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis. Parasit Vectors (2014) 7:61. doi:10.1186/1756-3305-7-61
130. Musa AM, Noazin S, Khalil EA, Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consider- ation. Trans R Soc Trop Med Hyg (2010) 104(1):1-2. doi:10.1016/j.trstmh.2009.07.026
131. Moll H, Berberich C. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis. Immunobiology (2001) 204(5):659-66. doi:10.1078/0171-2985-00105
132. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol (2003) 170(11):5625-9. doi:10.4049/jimmunol.170.11.5625
133. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun (2003) 71(11):6453-62. doi:10.1128/IAI.71.11.6453-6462.2003
134. Zubairi S, Sanos SL, Hill S, Kaye PM. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol (2004) 34(5):1433-40. doi:10.1002/eji.200324021
135. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun (2002) 70(11):6284-93. doi:10.1128/IAI.70.11.6284-6293.2002
136. Murray HW. Interleukin 10 receptor blockade - pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop (2005) 93(3):295-301. doi:10.1016/j.actatropica.2004.11.008
137. Shakya N, Sane SA, Vishwakarma P, Gupta S. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental visceral leishmaniasis. Exp Parasitol (2012) 131(3):377-82. doi:10.1016/j.exppara.2012.05.007
138. Karmakar S, Bhaumik SK, Paul J, De T. TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog (2012) 8(4):e1002646. doi:10.1371/journal.ppat.1002646